<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03099538</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#16-008302</org_study_id>
    <nct_id>NCT03099538</nct_id>
  </id_info>
  <brief_title>Ixekizumab in the Treatment of Bullous Pemphigoid</brief_title>
  <official_title>Ixekizumab in the Treatment of Bullous Pemphigoid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently, Interleukin (IL)-17 has been identified as a key driver of chronic inflammation in&#xD;
      Bullous Pemphigoid (BP). Ixekizumab is a recombinant high-affinity fully human monoclonal&#xD;
      antibody that targets IL-17A Immunoglobulin gamma-1 (IgG1)/kappa-class. The purpose of this&#xD;
      study is to determine the effect of Ixekizumab on BP patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BP is the most common auto-immune blistering disease of the skin and causes significant&#xD;
      morbidity. BP disproportionally affects the elderly population and the current, non-specific&#xD;
      immunosuppressive therapies, in addition to patient comorbidities, are associated with a high&#xD;
      risk of infection related mortality. Neutrophils and their proteases have been shown to play&#xD;
      a major role in the cleavage of Bullous Pemphigoid 180 Antigen (BP180) in BP. Mast cells and&#xD;
      other cellular mediators also contribute to the pro-inflammatory environment within and&#xD;
      surrounding blisters of BP. However, the prior targeting of mast cells and basophils has&#xD;
      resulted in unpredictable disease control. Recently, IL-17 has been identified as a key&#xD;
      driver of chronic inflammation in BP. With the increasing aged population in the United&#xD;
      States, BP will increase in prevalence and the development of a more targeted approach will&#xD;
      be necessary to decrease morbidity and mortality. IL-17 inhibition with Ixekizumab may have&#xD;
      targeted, disease-modifying effects on BP. The primary objective is to test the effect of&#xD;
      Ixekizumab in the treatment of the autoimmune blistering disease, BP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 15, 2017</start_date>
  <completion_date type="Actual">June 6, 2019</completion_date>
  <primary_completion_date type="Actual">June 6, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a single center, exploratory, open-label, single-arm design study of 12 patients with BP. Treatment na√Øve and treatment refractory patients with BP will be treated with Ixekizumab. Patients who are non-responders, to physician choice standard of care, will undergo a washout period and will be enrolled in the study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cessation of Blister Formation</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Median time to cessation of blister formation during the 12 weeks of therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Bullous Pemphigoid Disease Activity Index (BPDAI)</measure>
    <time_frame>Week 0 and week 12</time_frame>
    <description>The change in Bullous Pemphigoid Disease Activity Index (BPDAI) from week 0 to 12 of treatment will be measured.The BPDAI is a standard scoring system for cutaneous disease activity and pruritus in BP. BPDAI is predictive of the likelihood of a subsequent flare. The BPDAI consists of scoring various types of lesions and creates a score ranging from 0 to 120. A score of greater than 56 is considered severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prednisone Dose (mg)</measure>
    <time_frame>Epoch 1 (washout- up to 4 weeks) Epoch 2 (week 0 to week 12) Epoch 3 (week 12 to week 16)</time_frame>
    <description>Average daily prednisone dose (mg) will be calculated for each Epoch.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-related Adverse Events as Assessed by the Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0).</measure>
    <time_frame>weeks 0 to 18</time_frame>
    <description>The clinical safety of Ixekizumab will be monitored with collection of vital signs, clinical examination, and clinical laboratory studies. Adverse events (AE) will be reported per the Common Terminology Criteria for Adverse Events (CTCAEv4.0), a descriptive terminology which can be utilized for AE reporting. A grading (severity) scale is provided for each AE Grade refers to the severity of the AE. The CTCAE displays Grades 1-5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in Immunoglobulin G Anti-Bullous Pemphigoid 180 and 230 Antibody (Anti-BP180 &amp; 230 IgG)</measure>
    <time_frame>week 0, 4, 8, 12</time_frame>
    <description>We will measure the anti-BP180&amp;230 antibodies through out treatment. These assays will be completed using and ELISA assay. Mayo medical labs references for anti-BP180&amp;230 (&lt;9.0 Units negative, &gt; or = 9.0 Units positive)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in Neutrophil and Eosinophil Counts</measure>
    <time_frame>week 0, 4, 8, 12</time_frame>
    <description>Neutrophil and eosinophil counts will be monitored throughout therapy. Mayo medical labs reports normal neutrophil levels (1.70-7.00X10(9)/L) and normal eosinophil levels (0.05-0.5X10(9)/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multiplex Cytokine Analysis</measure>
    <time_frame>week 0, 4, 8, 12</time_frame>
    <description>Multiplex cytokine analysis will be performed throughout therapy on Interleukin (IL)- 6, 17, 22, 23, Transforming growth factor beta (TGFb), and matrix-metalloprotease-9 (MMP9).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Bullous Pemphigoid</condition>
  <condition>Pemphigoid</condition>
  <arm_group>
    <arm_group_label>Ixekizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ixekizumab subcutaneous 160mg week 0, 80mg weeks 2, 4, 6, 8, 10, 12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixekizumab</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>Ixekizumab</arm_group_label>
    <other_name>Taltz</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Subjects eligible for inclusion in this study have to fulfill all of the following&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Subjects must be able to understand and comply with the requirements of the study and&#xD;
             communicate with the investigator. Subjects must give written, signed, and dated&#xD;
             informed consent before any study related activity is performed. When appropriate, a&#xD;
             legal representative will sign the informed consent according to local laws and&#xD;
             regulation&#xD;
&#xD;
          -  Both men and women must be at least 18 years of age at the time of screening&#xD;
&#xD;
          -  Subjects must have clinical, histological, and serological features of BP&#xD;
&#xD;
          -  Urticarial plaques and/or vesicles and bullae&#xD;
&#xD;
          -  Characteristic eosinophilic spongiosis and/or subepidermal separation of the skin&#xD;
&#xD;
          -  Positive direct immunofluorescence (IgG and or C3 at the basement membrane zone) or&#xD;
             indirect immunofluorescence (IgG on the roof of salt- split skin) or positive&#xD;
             serologies on ELISA for BPAG1 or BPAG2&#xD;
&#xD;
          -  Subjects must have treatment naive BP or treatment refractory disease, as defined by&#xD;
             failure of at least one established treatment for BP&#xD;
&#xD;
          -  Candidate for systemic therapy, defined by&#xD;
&#xD;
          -  involvement of greater than 5 percent body surface area or moderate to extensive&#xD;
             disease as defined by: the mean number of new bullae and urticarial plaques that have&#xD;
             appeared over the course of 3 days as determined by the investigator or referring&#xD;
             physician (moderate disease defined by greater than 1 and less than 10 new bullae and&#xD;
             greater than 5 urticarial plaques and extensive disease by greater than 10 new bullae)&#xD;
&#xD;
          -  Failure of prior therapy&#xD;
&#xD;
          -  Topical treatment&#xD;
&#xD;
          -  Systemic immunosuppressant&#xD;
&#xD;
          -  Oral antibiotics and/or niacinamide&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects fulfilling any of the following criteria are not eligible for inclusion in this&#xD;
        study. In order to ensure the recruitment of a representative sample of all eligible&#xD;
        subjects, the investigator may apply no additional exclusions.&#xD;
&#xD;
          -  Forms of BP other than classic BP (e.g. mucous membrane BP, Brunsting-Perry BP, p200&#xD;
             BP, p105 BP, or BP with concomitant pemphigus vulgaris Drug-induced BP (e.g., new&#xD;
             onset or current exacerbation from angiotensin converting enzyme inhibitors,&#xD;
             penicillamine, furosemide, phenacetin)&#xD;
&#xD;
          -  Subjects who are receiving treatments known to worsen BP and use of penicillamine or&#xD;
             phenacetin and those on angiotensin converting enzyme inhibitors or furosemide who&#xD;
             have not been on a stable dose at least 4 weeks prior to enrollment.&#xD;
&#xD;
          -  Ongoing use of prohibited treatments.&#xD;
&#xD;
          -  Previous exposure to Ixekizumab or any other biologic drug directly targeting IL-17A&#xD;
             or IL-17 (receptor A)RA&#xD;
&#xD;
          -  Use of any other investigational drugs within 5 half-lives of the investigational&#xD;
             treatment before study drug initiation or until the pharmacodynamics effect has&#xD;
             returned to baseline, whichever is longer&#xD;
&#xD;
          -  Previous use of IL-20 monoclonal antibody&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women (pregnancy is defined as the state of a female&#xD;
             after conception and until the termination of gestation, confirmed by a positive human&#xD;
             chorionic gonadotropin (hCG) laboratory test)&#xD;
&#xD;
          -  Women of childbearing potential [Post-menopausal or not of child-bearing potential is&#xD;
             defined by: 1 year of natural (spontaneous) amenorrhea or Surgical bilateral&#xD;
             oophorectomy (with or without hysterectomy), total hysterectomy or tubal ligation at&#xD;
             least 6 weeks ago. Oophorectomy alone must confirmed by follow up hormone level&#xD;
             assessment to be considered not of child-bearing potential, defined as all women&#xD;
             physiologically capable of becoming pregnant, unless they are using basic methods of&#xD;
             contraception which includes:&#xD;
&#xD;
          -  Total abstinence (Periodic abstinence and withdrawal are not acceptable methods of&#xD;
             contraception)&#xD;
&#xD;
          -  Female sterilization (bilateral oophorectomy with or without hysterectomy), total&#xD;
             hysterectomy, or tubal ligation at least 6 weeks before taking study treatment.&#xD;
             Oophorectomy alone requires follow up hormone level assessment for fertility.&#xD;
&#xD;
          -  Male sterilization (at least 6 months prior to screening). The vasectomized male&#xD;
             partner should be the sole partner for that subject.&#xD;
&#xD;
          -  Barrier methods of contraception: condom or occlusive cap. Use of oral, injected or&#xD;
             implanted hormonal methods of contraception or other forms or hormonal contraception&#xD;
             that have complete efficacy (failure less than 1 percent). (The dose of the&#xD;
             contraceptive should be stable for 3 months)&#xD;
&#xD;
          -  Active ongoing inflammatory diseases of the skin other than BP that might confound the&#xD;
             evaluation of the benefit of Ixekizumab&#xD;
&#xD;
          -  Underlying condition (including, but not limited to metabolic, hematologic, renal,&#xD;
             hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal&#xD;
             conditions) which, in the opinion of the investigator, significantly immunocompromises&#xD;
             the subject and/or places the subject at unacceptable risk for receiving an&#xD;
             immunomodulatory therapy Investigator discretion should be used for subjects with&#xD;
             pre-existing or recent-onset central or peripheral nervous system demyelinating&#xD;
             disorders Significant medical problems, including but not limited to the following:&#xD;
             uncontrolled hypertension, congestive heart failure (New York Heart Association (NYHA)&#xD;
             status of class III or IV)&#xD;
&#xD;
          -  Serum creatinine level exceeding 2.0 mg per dL (176.8 micro mol per L) at screening&#xD;
&#xD;
          -  Total white blood cell (WBC) count less than 2,500 per microL, platelets less than&#xD;
             100,000 per microL, neutrophils less1500/microL or hemoglobin less than 8.5 g per dL,&#xD;
             at screening&#xD;
&#xD;
          -  Active systemic infections during the 2 weeks prior to randomization (common cold&#xD;
             viruses not included) or any infection that reoccurs on a regular basis.&#xD;
&#xD;
          -  Investigator discretion should be used regarding subjects who have traveled or resided&#xD;
             in areas of endemic mycoses, such as histoplasmosis, coccidioidomycosis or&#xD;
             blastomycosis and for subjects with underlying conditions that may predispose them to&#xD;
             infection, such as advanced or inadequately controlled diabetes. Due to its endemic&#xD;
             nature in Arizona, coccidioidomycosis screening is performed at baseline. A history of&#xD;
             a disseminated coccidioidomycosis infection will exclude subjects.&#xD;
&#xD;
          -  History of an ongoing, chronic or recurrent infectious disease, or evidence of&#xD;
             tuberculosis infection as defined by a positive or indeterminate QuantiFERON&#xD;
             Tuberculosis (TB)-Gold test (QFT) at screening.&#xD;
&#xD;
          -  Subjects with a positive QFT test may participate in the study if a full tuberculosis&#xD;
             work up (according to local practice/guidelines) is completed within 12 weeks prior to&#xD;
             establishes conclusively that the subject has no evidence of active tuberculosis.&#xD;
&#xD;
        If the presence of latent tuberculosis is established, then treatment must have been&#xD;
        initiated and maintained according to local country guidelines for at least 4 weeks prior&#xD;
        to randomization.&#xD;
&#xD;
          -  Past medical history of, or current infection with, human immunodeficiency virus&#xD;
             (HIV), hepatitis B or hepatitis C prior to new diagnosis at screening&#xD;
&#xD;
          -  History of lymphoproliferative disease and or any known malignancy and/or history of&#xD;
             malignancy of any organ system within the past 5 years&#xD;
&#xD;
        Exceptions include:&#xD;
&#xD;
        For skin squamous cell carcinoma in situ and or well differentiate squamous cell carcinoma&#xD;
        and/or basal cell carcinoma and or actinic keratosis and/or melanoma in situ that have been&#xD;
        treated with no evidence of recurrence For the cervix carcinoma that has been removed For&#xD;
        the colon non-invasive malignant colon polyps that have been removed&#xD;
&#xD;
          -  Current severe progressive or uncontrolled disease which the investigator renders the&#xD;
             subject unsuitable for the trial or puts the subject at increased risk Inability or&#xD;
             unwillingness to undergo repeated venipuncture&#xD;
&#xD;
          -  Any medical or psychiatric condition which, in the investigator's opinion, would keep&#xD;
             the subject from adhering to the protocol or completing the study per protocol&#xD;
&#xD;
          -  History or evidence of ongoing alcohol or drug abuse, within the last 6 months prior&#xD;
             to the initiation of therapy&#xD;
&#xD;
          -  Plans for administration of live vaccines during the study period or in the 12 weeks&#xD;
             prior to the initiation of therapy&#xD;
&#xD;
          -  Bacillus Calmette-Guerin (BCG) vaccination within 12 months of starting the study or&#xD;
             with 12 months after completing the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aaron Mangold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 21, 2017</study_first_submitted>
  <study_first_submitted_qc>March 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <results_first_submitted>April 27, 2020</results_first_submitted>
  <results_first_submitted_qc>May 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 21, 2020</results_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Aaron R. Mangold</investigator_full_name>
    <investigator_title>Assistant Professor of Dermatology</investigator_title>
  </responsible_party>
  <keyword>Ixekizumab</keyword>
  <keyword>Bullous Pemphigoid</keyword>
  <keyword>Pemphigoid</keyword>
  <keyword>IL17</keyword>
  <keyword>IL-17</keyword>
  <keyword>Interleukin 17</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemphigoid, Bullous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ixekizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT03099538/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ixekizumab</title>
          <description>Ixekizumab subcutaneous 160mg week 0, 80mg weeks 2, 4, 6, 8, 10, 12.&#xD;
Ixekizumab: Subcutaneous injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ixekizumab</title>
          <description>Ixekizumab subcutaneous 160mg week 0, 80mg weeks 2, 4, 6, 8, 10, 12.&#xD;
Ixekizumab: Subcutaneous injection</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.8" spread="6.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cessation of Blister Formation</title>
        <description>Median time to cessation of blister formation during the 12 weeks of therapy.</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>Endpoint was not achieved as there was no cession of blisters.</population>
        <group_list>
          <group group_id="O1">
            <title>Ixekizumab</title>
            <description>Ixekizumab subcutaneous 160mg week 0, 80mg weeks 2, 4, 6, 8, 10, 12.&#xD;
Ixekizumab: Subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Cessation of Blister Formation</title>
          <description>Median time to cessation of blister formation during the 12 weeks of therapy.</description>
          <population>Endpoint was not achieved as there was no cession of blisters.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Insufficient number of participants with events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Bullous Pemphigoid Disease Activity Index (BPDAI)</title>
        <description>The change in Bullous Pemphigoid Disease Activity Index (BPDAI) from week 0 to 12 of treatment will be measured.The BPDAI is a standard scoring system for cutaneous disease activity and pruritus in BP. BPDAI is predictive of the likelihood of a subsequent flare. The BPDAI consists of scoring various types of lesions and creates a score ranging from 0 to 120. A score of greater than 56 is considered severe disease.</description>
        <time_frame>Week 0 and week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ixekizumab</title>
            <description>Ixekizumab subcutaneous 160mg week 0, 80mg weeks 2, 4, 6, 8, 10, 12.&#xD;
Ixekizumab: Subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bullous Pemphigoid Disease Activity Index (BPDAI)</title>
          <description>The change in Bullous Pemphigoid Disease Activity Index (BPDAI) from week 0 to 12 of treatment will be measured.The BPDAI is a standard scoring system for cutaneous disease activity and pruritus in BP. BPDAI is predictive of the likelihood of a subsequent flare. The BPDAI consists of scoring various types of lesions and creates a score ranging from 0 to 120. A score of greater than 56 is considered severe disease.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" spread="17.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" spread="24.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prednisone Dose (mg)</title>
        <description>Average daily prednisone dose (mg) will be calculated for each Epoch.</description>
        <time_frame>Epoch 1 (washout- up to 4 weeks) Epoch 2 (week 0 to week 12) Epoch 3 (week 12 to week 16)</time_frame>
        <population>Only one subject remained in the study by Epoch 3 timepoint (week 12 to 16)</population>
        <group_list>
          <group group_id="O1">
            <title>Ixekizumab</title>
            <description>Ixekizumab subcutaneous 160mg week 0, 80mg weeks 2, 4, 6, 8, 10, 12.&#xD;
Ixekizumab: Subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Prednisone Dose (mg)</title>
          <description>Average daily prednisone dose (mg) will be calculated for each Epoch.</description>
          <population>Only one subject remained in the study by Epoch 3 timepoint (week 12 to 16)</population>
          <units>mg/d</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Epoch 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epoch 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.42" spread="9.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epoch 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-related Adverse Events as Assessed by the Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0).</title>
        <description>The clinical safety of Ixekizumab will be monitored with collection of vital signs, clinical examination, and clinical laboratory studies. Adverse events (AE) will be reported per the Common Terminology Criteria for Adverse Events (CTCAEv4.0), a descriptive terminology which can be utilized for AE reporting. A grading (severity) scale is provided for each AE Grade refers to the severity of the AE. The CTCAE displays Grades 1-5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE.</description>
        <time_frame>weeks 0 to 18</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ixekizumab</title>
            <description>Ixekizumab subcutaneous 160mg week 0, 80mg weeks 2, 4, 6, 8, 10, 12.&#xD;
Ixekizumab: Subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-related Adverse Events as Assessed by the Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0).</title>
          <description>The clinical safety of Ixekizumab will be monitored with collection of vital signs, clinical examination, and clinical laboratory studies. Adverse events (AE) will be reported per the Common Terminology Criteria for Adverse Events (CTCAEv4.0), a descriptive terminology which can be utilized for AE reporting. A grading (severity) scale is provided for each AE Grade refers to the severity of the AE. The CTCAE displays Grades 1-5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Decrease in Immunoglobulin G Anti-Bullous Pemphigoid 180 and 230 Antibody (Anti-BP180 &amp; 230 IgG)</title>
        <description>We will measure the anti-BP180&amp;230 antibodies through out treatment. These assays will be completed using and ELISA assay. Mayo medical labs references for anti-BP180&amp;230 (&lt;9.0 Units negative, &gt; or = 9.0 Units positive)</description>
        <time_frame>week 0, 4, 8, 12</time_frame>
        <population>This outcome measure was not achieved due to lack to sample to run assays.</population>
        <group_list>
          <group group_id="O1">
            <title>Ixekizumab</title>
            <description>Ixekizumab subcutaneous 160mg week 0, 80mg weeks 2, 4, 6, 8, 10, 12.&#xD;
Ixekizumab: Subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Decrease in Immunoglobulin G Anti-Bullous Pemphigoid 180 and 230 Antibody (Anti-BP180 &amp; 230 IgG)</title>
          <description>We will measure the anti-BP180&amp;230 antibodies through out treatment. These assays will be completed using and ELISA assay. Mayo medical labs references for anti-BP180&amp;230 (&lt;9.0 Units negative, &gt; or = 9.0 Units positive)</description>
          <population>This outcome measure was not achieved due to lack to sample to run assays.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Decrease in Neutrophil and Eosinophil Counts</title>
        <description>Neutrophil and eosinophil counts will be monitored throughout therapy. Mayo medical labs reports normal neutrophil levels (1.70-7.00X10(9)/L) and normal eosinophil levels (0.05-0.5X10(9)/L)</description>
        <time_frame>week 0, 4, 8, 12</time_frame>
        <population>This outcome measure was not achieved due to lack of data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ixekizumab</title>
            <description>Ixekizumab subcutaneous 160mg week 0, 80mg weeks 2, 4, 6, 8, 10, 12.&#xD;
Ixekizumab: Subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Decrease in Neutrophil and Eosinophil Counts</title>
          <description>Neutrophil and eosinophil counts will be monitored throughout therapy. Mayo medical labs reports normal neutrophil levels (1.70-7.00X10(9)/L) and normal eosinophil levels (0.05-0.5X10(9)/L)</description>
          <population>This outcome measure was not achieved due to lack of data.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Multiplex Cytokine Analysis</title>
        <description>Multiplex cytokine analysis will be performed throughout therapy on Interleukin (IL)- 6, 17, 22, 23, Transforming growth factor beta (TGFb), and matrix-metalloprotease-9 (MMP9).</description>
        <time_frame>week 0, 4, 8, 12</time_frame>
        <population>This outcome measure was not achieved due to lack of sample to run assays.</population>
        <group_list>
          <group group_id="O1">
            <title>Ixekizumab</title>
            <description>Ixekizumab subcutaneous 160mg week 0, 80mg weeks 2, 4, 6, 8, 10, 12.&#xD;
Ixekizumab: Subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Multiplex Cytokine Analysis</title>
          <description>Multiplex cytokine analysis will be performed throughout therapy on Interleukin (IL)- 6, 17, 22, 23, Transforming growth factor beta (TGFb), and matrix-metalloprotease-9 (MMP9).</description>
          <population>This outcome measure was not achieved due to lack of sample to run assays.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for each subject from baseline until 30 days post-study participation, for a total of approximately four to five months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ixekizumab</title>
          <description>Ixekizumab subcutaneous 160mg week 0, 80mg weeks 2, 4, 6, 8, 10, 12.&#xD;
Ixekizumab: Subcutaneous injection</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dry eyes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Rib pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Skin Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Facial swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Staphylococcal overgrowth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Aaron R. Mangold, MD</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>480-301-4256</phone>
      <email>mangold.aaron@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

